Most cited papers in Peptidase Inhibition and Analysis
What are the most cited papers in Peptidase Inhibition and Analysis?
The most cited paper in Peptidase Inhibition and Analysis is "Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene" (Dennis J. Slamon, Gary M. Clark, Steven Wong et al., 1987), with 11,844 citations. Next come "Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer" (10,303) and "Peptidotriazoles on Solid Phase: [1,2,3]-Triazoles by Regiospecific Copper(I)-Catalyzed 1,3-Dipolar Cycloadditions of Terminal Alkynes to Azides" (8,627).
Showing 50 of 100 papers. Every paper with more than 1,504 citations is listed.
| # | Paper | ||
|---|---|---|---|
| 1 | Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene Dennis J. Slamon, Gary M. Clark, Steven Wong et al. · Science | 9 Jan 1987 | 11,844 |
| 2 | Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer Martin Reck, Delvys Rodríguez‐Abreu, Andrew George Robinson et al. · New England Journal of Medicine | 9 Oct 2016 | 10,303 |
| 3 | Peptidotriazoles on Solid Phase: [1,2,3]-Triazoles by Regiospecific Copper(I)-Catalyzed 1,3-Dipolar Cycloadditions of Terminal Alkynes to Azides Christian Wenzel Tornøe, Caspar Elo Christensen, Morten Meldal · The Journal of Organic Chemistry | 2 Apr 2002 | 8,627 |
| 4 | In situ click chemistry generation of cyclooxygenase-2 inhibitors Atul Bhardwaj, Jatinder Paul Kaur, Melinda Wuest et al. · Nature Communications | 9 Feb 2017 | 7,563 |
| 5 | Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Yung‐Jue Bang, Eric Van Cutsem, Andrea Feyereislova et al. · The Lancet | Aug 2010 | 7,405 |
| 6 | Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer Edward B. Garon et al. · New England Journal of Medicine | 19 Apr 2015 | 6,312 |
| 7 | New functions for the matrix metalloproteinases in cancer progression Mikala Egeblad, Zena Werb · Nature reviews. Cancer | Mar 2002 | 6,127 |
| 8 | Erlotinib in Previously Treated Non–Small-Cell Lung Cancer Frances Alice Shepherd, José Rodrigues Pereira, Tudor–Eliade Ciuleanu et al. · New England Journal of Medicine | 13 Jul 2005 | 5,471 |
| 9 | Matrix Metalloproteinases: Regulators of the Tumor Microenvironment Kai Kessenbrock, Vicki Plaks, Zena Werb · Cell | Apr 2010 | 5,146 |
| 10 | International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma S. Vincent Rajkumar et al. · The Lancet Oncology | 26 Oct 2014 | 5,031 |
| 11 | New Perspectives in Cell Adhesion: RGD and Integrins Erkki I. Ruoslahti, Michael D. Pierschbacher · Science | 23 Oct 1987 | 4,905 |
| 12 | Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial Achim Rittmeyer et al. · The Lancet | 12 Dec 2016 | 4,817 |
| 13 | Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases Robert Visse, Hideaki Nagase · Circulation Research | May 2003 | 4,573 |
| 14 | Remodelling the extracellular matrix in development and disease Caroline Bonnans, Jonathan Chou, Zena Werb · Nature Reviews Molecular Cell Biology | 21 Nov 2014 | 4,490 |
| 15 | Trastuzumab-Induced Hepatotoxicity: A Case Report Darko Vucicevic, Elizabeth J. Carey, Nina J. Karlin · Breast Care | 2013 | 4,419 |
| 16 | Cancer Metastasis: Building a Framework Gaorav P. Gupta, Joan Massagué · Cell | Nov 2006 | 4,346 |
| 17 | Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions Chunaram Choudhary, Chanchal Kumar, Florian Gnad et al. · Science | 16 Jul 2009 | 4,088 |
| 18 | How Matrix Metalloproteinases Regulate Cell Behavior Mark D. Sternlicht, Zena Werb · Annual Review of Cell and Developmental Biology | Nov 2001 | 3,957 |
| 19 | The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Daniel J. Drucker, Michael Albrecht Nauck · The Lancet | Nov 2006 | 3,921 |
| 20 | Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer Luis G Paz-Ares et al. · New England Journal of Medicine | 25 Sep 2018 | 3,710 |
| 21 | Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule Michael D. Pierschbacher, Erkki I. Ruoslahti · Nature | May 1984 | 3,684 |
| 22 | Biology of Incretins: GLP-1 and GIP Laurie L. Baggio, Daniel J. Drucker · Gastroenterology | May 2007 | 3,643 |
| 23 | First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer Leora Horn et al. · New England Journal of Medicine | 25 Sep 2018 | 3,637 |
| 24 | Effect of pegylation on pharmaceuticals J. Milton Harris, Robert B. Chess · Nature Reviews Drug Discovery | 28 Feb 2003 | 3,437 |
| 25 | Structure and function of matrix metalloproteinases and TIMPs Hiroyuki Nagase, Robert Visse, G MURPHY · Cardiovascular Research | 6 Jan 2006 | 3,436 |
| 26 | The Complete Atomic Structure of the Large Ribosomal Subunit at 2.4 Å Resolution Nenad Ban, Poul Nissen, Jeffrey L. Hansen et al. · Science | 11 Aug 2000 | 3,334 |
| 27 | Matrix metalloproteinases and their inhibitors in connective tissue remodeling J. Frederick Woessner · The FASEB Journal | May 1991 | 3,305 |
| 28 | PROTAC targeted protein degraders: the past is prologue Miklós Békés, David R. Langley, Craig M. Crews · Nature Reviews Drug Discovery | 18 Jan 2022 | 3,294 |
| 29 | International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma Shaji Kunnathu Kumar et al. · The Lancet Oncology | 26 Jul 2016 | 3,102 |
| 30 | Matrix Metalloproteinases: A Review Henning Birkedal‐Hansen, William G. I. Moore, Malena Bodden et al. · Critical Reviews in Oral Biology & Medicine | 1993 | 2,995 |
| 31 | Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial Louis Fehrenbacher, Alexander I. Spira, Marcus D. Ballinger et al. · The Lancet | 9 Mar 2016 | 2,823 |
| 32 | Protein Purification by Affinity Chromatography Pedro Cuatrecasas · Journal of Biological Chemistry | Jun 1970 | 2,803 |
| 33 | Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations Lisa M. Coussens, Barbara Fingleton, Lynn McCormick Matrisian · Science | 29 Mar 2002 | 2,775 |
| 34 | Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation L. A. Liotta, Patricia Schriver Steeg, William George Stetler‐Stevenson · Cell | 1991 | 2,761 |
| 35 | Trastuzumab — Mechanism of Action and Use in Clinical Practice Clifford A. Hudis · New England Journal of Medicine | 4 Jul 2007 | 2,603 |
| 36 | A Calcineurin-Dependent Transcriptional Pathway for Cardiac Hypertrophy Jeffery D. Molkentin, Jianrong Lu, Christopher L. Antos et al. · Cell | Apr 1998 | 2,595 |
| 37 | A novel heterodimeric cysteine protease is required for interleukin-1βprocessing in monocytes Nancy A. Thornberry et al. · Nature | Apr 1992 | 2,592 |
| 38 | A matrix metalloproteinase expressed on the surface of invasive tumour cells Hiroshi Sato, Takahisa Takino, Yasunori Okada et al. · Nature | Jul 1994 | 2,576 |
| 39 | Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation Kathleen M. Sakamoto, Kyung B. Kim, Akiko Kumagai et al. · Proceedings of the National Academy of Sciences | 3 Jul 2001 | 2,570 |
| 40 | Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer José Baselga, Javier Cortés, Sung‐Bae Kim et al. · New England Journal of Medicine | 7 Dec 2011 | 2,559 |
| 41 | STRUCTURE AND FUNCTIONS OF THE 20S AND 26S PROTEASOMES Olivier Coux, Keiji Tanaka, Alfred L. Goldberg · Annual Review of Biochemistry | Jun 1996 | 2,447 |
| 42 | Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product. Gérard I. Evan, George K. Lewis, Gary M. Ramsay et al. · Molecular and Cellular Biology | Dec 1985 | 2,439 |
| 43 | A review of saliva: Normal composition, flow, and function Sue P. Humphrey, Russell T. Williamson · Journal of Prosthetic Dentistry | Feb 2001 | 2,411 |
| 44 | HDAC6 is a microtubule-associated deacetylase Charlotte C. Hubbert, Amaris R. Guardiola, Rong Shao et al. · Nature | May 2002 | 2,409 |
| 45 | The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity Jude R. Canon et al. · Nature | 30 Oct 2019 | 2,329 |
| 46 | Structure of 20S proteasome from yeast at 2.4Å resolution M. Groll, Lars Ditzel, Jan Löwe et al. · Nature | Apr 1997 | 2,271 |
| 47 | Multiple myeloma Noopur S Raje, Kenneth Carl Anderson · Current Treatment Options in Oncology | Feb 2000 | 2,176 |
| 48 | RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor Linda M. McLatchie, Neil J. Fraser, Martin J. Main et al. · Nature | May 1998 | 2,163 |
| 49 | Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC Victor Stalin Raj, Huihui Mou, Saskia L. Smits et al. · Nature | Mar 2013 | 2,153 |
| 50 | Tumor metastasis: mechanistic insights and clinical challenges Patricia Schriver Steeg · Nature Medicine | Aug 2006 | 2,152 |
Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for a field when OpenAlex files it under one of the field's topics; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.